RATIONALE AND OBJECTIVES: The authors evaluate MS-325, a new albumin-targeted magnetic resonance imaging (MRI) contrast agent, for its pharmacokinetics, biodistribution, and elimination characteristics in multiple animal species. METHODS: Studies were performed in rats, rabbits, and nonhuman primates at intravenous doses ranging from 0.025 to 0.20 mmol/kg. Concentrations of MS-325 in blood, urine, feces, and organs were determined using gadolinium-153-labeled MS-325 and gamma counting or by using non-labeled MS-325 and inductively coupled plasma atomic emission spectrometry. RESULTS: In rabbits and nonhuman primates, MS-325 is approximately 85% to 95% bound to serum proteins and, as a result, exhibits low volume of distribution (Vd) values, 0.11 to 0.14 L/kg, and a long elimination half-life (Te1/2), 2 to 3 hours. Some dose-dependence in the parameters is apparent in rabbits. MS-325 is eliminated primarily through the renal system in non-human primates. In contrast, the behavior of MS-325 in rats is different, exhibiting increased biliary excretion, a larger Vd value, and a shorter Te1/2. CONCLUSIONS: The pharmacokinetics and elimination profile of MS-325, including vascular retention and renal excretion, are favorable for use in humans as an intravascular contrast agent for MRI.
RATIONALE AND OBJECTIVES: The authors evaluate MS-325, a new albumin-targeted magnetic resonance imaging (MRI) contrast agent, for its pharmacokinetics, biodistribution, and elimination characteristics in multiple animal species. METHODS: Studies were performed in rats, rabbits, and nonhuman primates at intravenous doses ranging from 0.025 to 0.20 mmol/kg. Concentrations of MS-325 in blood, urine, feces, and organs were determined using gadolinium-153-labeled MS-325 and gamma counting or by using non-labeled MS-325 and inductively coupled plasma atomic emission spectrometry. RESULTS: In rabbits and nonhuman primates, MS-325 is approximately 85% to 95% bound to serum proteins and, as a result, exhibits low volume of distribution (Vd) values, 0.11 to 0.14 L/kg, and a long elimination half-life (Te1/2), 2 to 3 hours. Some dose-dependence in the parameters is apparent in rabbits. MS-325 is eliminated primarily through the renal system in non-human primates. In contrast, the behavior of MS-325 in rats is different, exhibiting increased biliary excretion, a larger Vd value, and a shorter Te1/2. CONCLUSIONS: The pharmacokinetics and elimination profile of MS-325, including vascular retention and renal excretion, are favorable for use in humans as an intravascular contrast agent for MRI.
Authors: Stephan Metz; Ambros J Beer; Marcus Settles; Jaroslav Pelisek; René M Botnar; Ernst J Rummeny; Peter Heider Journal: Int J Cardiovasc Imaging Date: 2010-10-24 Impact factor: 2.357
Authors: He Wei; Oliver T Bruns; Michael G Kaul; Eric C Hansen; Mariya Barch; Agata Wiśniowska; Ou Chen; Yue Chen; Nan Li; Satoshi Okada; Jose M Cordero; Markus Heine; Christian T Farrar; Daniel M Montana; Gerhard Adam; Harald Ittrich; Alan Jasanoff; Peter Nielsen; Moungi G Bawendi Journal: Proc Natl Acad Sci U S A Date: 2017-02-13 Impact factor: 11.205
Authors: M Anzidei; A Napoli; D Geiger; B Cavallo Marincola; C Zini; F Zaccagna; P Di Paolo; C Catalano; R Passariello Journal: Radiol Med Date: 2010-02-22 Impact factor: 3.469
Authors: M M Stollenwerk; I Pashkunova-Martic; C Kremser; H Talasz; G C Thurner; A A Abdelmoez; E A Wallnöfer; A Helbok; E Neuhauser; N Klammsteiner; L Klimaschewski; E von Guggenberg; E Fröhlich; B Keppler; W Jaschke; P Debbage Journal: Histochem Cell Biol Date: 2010-02-20 Impact factor: 4.304
Authors: Chunying Shu; Frank D Corwin; Jianfei Zhang; Zhijian Chen; Jonathan E Reid; Minghao Sun; Wei Xu; Jae Hyun Sim; Chunru Wang; Panos P Fatouros; Alan R Esker; Harry W Gibson; Harry C Dorn Journal: Bioconjug Chem Date: 2009-06 Impact factor: 4.774